Abstract
Allergen-specific immunotherapy (AIT) is a disease-modifying treatment for house dust mite (HDM) allergic asthma and rhinitis, typically requiring a three-year commitment. However, identifying early indicators of efficacy remains a challenge. This study evaluates non-invasive airway inflammation parameters—fractional exhaled nitric oxide (FeNO), nasal nitric oxide (FnNO), and impulse oscillometry (IOS)—alongside serum biomarkers as potential tools for monitoring early response to AIT. The results indicate that these markers significantly improve within the first year, providing objective evidence of treatment success.
Introduction
Allergen-specific immunotherapy (AIT) is unique in its ability to modify the underlying allergic disease rather than merely managing symptoms. Despite its long-term benefits, the duration of treatment (3–5 years) often leads to patient non-adherence, especially if clinical improvements are not immediately apparent. In patients with mild asthma, traditional lung function tests like spirometry (FEV1) often exhibit a "ceiling effect," appearing normal even when subclinical inflammation persists. There is a critical need for sensitive, non-invasive biomarkers that can demonstrate treatment efficacy within the first six to twelve months.
Methods
This single-arm observational study followed 22 adult patients (mean age ~34 years) with mild HDM-allergic asthma and concomitant allergic rhinitis. All participants underwent subcutaneous immunotherapy (SCIT) using Dermatophagoides pteronyssinus (Der p) extract. Clinical evaluations were performed at baseline, six months, and one year.
The researchers assessed several candidate biomarkers:
- Airway Inflammation: FeNO (lung) and FnNO (nasal) levels, which measure nitric oxide as a byproduct of allergic inflammation.
- Small Airway Function: Impulse oscillometry (IOS), which uses sound waves to measure airway resistance (R5 and R20) during normal breathing, avoiding the effort-dependency of spirometry.
- Serum Biomarkers: Der p-specific IgE (sIgE) and IgG4 (sIgG4) levels.
- Clinical Outcomes: Visual Analogue Scale (VAS) for symptoms and standardized medication scores.
Results
The study found significant improvements across clinical, physiological, and immunological parameters within the first year of treatment, often appearing as early as six months.
Clinical and Inflammatory Improvements
Symptom scores (VAS) and medication requirements decreased significantly by the six-month mark and continued to improve through one year. Correspondingly, markers of allergic inflammation showed a marked decline. FeNO levels dropped from a baseline of 56.45 ppb to 21.82 ppb at one year ($P < 0.001$), while FnNO decreased from 688.05 ppb to 489.84 ppb.
Airway Mechanics and IOS
While standard spirometry metrics (FEV1) showed no significant change over the year, IOS parameters revealed significant improvements in small airway function. Specifically, R5 (total airway resistance) decreased from 124.82 to 102.09 KpaL⁻¹s⁻¹ ($P < 0.001$). This confirms that IOS is a more sensitive tool for detecting "silent" physiological improvements in the peripheral airways of mild asthma patients.
Immunological Shift
Serum analysis showed a dramatic increase in Der p-specific IgG4 (blocking antibodies), rising from 489.27 AU/ml to 2330.78 AU/ml. While sIgE levels did not change significantly in isolation, the sIgE/sIgG4 ratio decreased significantly, serving as a robust indicator of the immunological shift toward allergen tolerance.
Discussion
The findings highlight the "one airway, one disease" concept, as immunotherapy concurrently reduced inflammation in both the upper (nasal) and lower (lung) respiratory tracts. The sensitivity of IOS in detecting changes where spirometry failed underscores its value in monitoring patients with mild asthma who may otherwise appear "normal" on standard tests. Furthermore, the rapid improvement seen within the first six months suggests that these biomarkers can provide early "proof of concept," potentially increasing patient motivation and adherence to the long-term AIT regimen.
Conclusion
Non-invasive parameters such as FeNO, FnNO, and IOS R5 are effective biomarkers for evaluating the early efficacy of HDM immunotherapy. Additionally, the sIgE/sIgG4 ratio provides a reliable immunological metric for treatment response. Incorporating these tools into routine clinical practice could enhance the personalized management of allergic asthma and rhinitis by providing objective evidence of improvement long before the treatment course is complete.
Summary updated